Sumitomo Chemical Co., Ltd.

Aeluma reported total revenue of $4.5 million for fiscal 2026, near the high end of its guidance, as the company pivots toward commercializing high-speed photodetectors and quantum dot lasers for the AI datacom market. Fourth-quarter revenue was $582,000, while the full-year GAAP net loss widened to $9.2 million, or $0.52 per share, from $3 million, or $0.23 per share, in fiscal 2025. Adjusted EBITDA was negative $5.2 million for the year, compared to positive $186,000 in fiscal 2025, driven by increased headcount and operating expenses. The company ended the year with $56 million in cash and no debt, after raising $20.1 million through its ATM facility. For fiscal 2027, Aeluma expects to recognize approximately $2.3 million of booked government contract revenue, with potential for an additional $2 million under discussion, and plans capital expenditures of $10 million to $12 million. Aeluma also announced a letter of intent with the Department of Commerce CHIPS R&D Office for up to $30 million in funding, which is likely to be accounted for as an equity investment rather than revenue, and a new agreement with Sumitomo Chemical Advanced Technologies to expand wafer production capacity.

Sumitomo Chemical's share price jumped more than 7 percent from the previous day on August 21, reaching 560 yen, its highest level in the past month. First-quarter operating profit for fiscal 2027 swelled to 61 billion yen, 2.4 times the same period a year earlier, while profit attributable to owners of the parent swung to a profit of 40.7 billion yen. Progress against full-year forecasts reached 34.5 percent for operating profit and 58.1 percent for net profit. Meanwhile, the equity ratio stands at 29.6 percent, less than half the chemical industry median of 64.4 percent, and some analysts point out that financial leverage is amplifying the swings in the share price.

Sumitomo Chemical reported a sharp rise in first-quarter core operating income to 62.3 billion yen, up 34.7 billion yen year on year, marking its second-best Q1 on record. Consolidated sales revenue reached 578.2 billion yen, while net income attributable to owners of the parent swung to a profit of 40.8 billion yen from a loss a year earlier. The Essential and Green Materials segment drove the improvement with core operating income of 27.2 billion yen, up 32.7 billion yen, helped by better margins at Petro Rabigh and inventory valuation gains. Agro and Life Solutions also contributed, with core operating income rising 7.4 billion yen to 9.6 billion yen on steady crop protection shipments and improved feed additive margins. However, ICT and Mobility Solutions saw core operating income fall 5.3 billion yen to 13 billion yen due to lower polarizing film prices and the absence of a prior-year gain, while Advanced Medical Solutions posted a core operating loss of 1.9 billion yen. The company maintained its full-year forecast, citing uncertainty from Middle East turmoil, and kept its annual dividend forecast at 16 yen per share.